Cissé, M., B. Halabisky, J. Harris, N. Devidze, D. B. Dubal, B. Sun, A. Orr, G. Lotz, D. H. Kim, P. Hamto, K. Ho, G. Q. Yu, and L. Mucke. 2011. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469(7328):47-52.

Clozel, M. 2011. Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research. Sci Transl Med 3(67):67cm2.

Conn, P. J., and B. L. Roth. 2008. Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings. Neuropsychopharm 33(9):2048-2060.

Crabbe, J. C., D. Wahlsten, and B. C. Dudek. 1999. Genetics of mouse behavior: Interactions with laboratory environment. Science 284(5420):1670-1672.

deIpolyi, A. R., K. P. Rankin, L. Mucke, B. L. Miller, and M. L. Gorno-Tempini. 2007. Spatial cognition and the human navigation network in AD and MCI. Neurology 69(10):986-997.

Easterbook, P. J., J. A. Berlin, R. Gopalan, and D. R. Matthews. 1991. Publication bias in clinical research. Lancet 337(8746):867-872.

Halliday, G.M. 2001. A review of the neuropathology of schizophrenia. Clin Exp Pharmacol 28(1-2):64-65.

IOM (Institute of Medicine). 2010. Extending the spectrum of precompetitive collaboration in oncology research: Workshop summary. Washington, DC: The National Academies Press.

Kaur, T., and K. S. Cadenhead. 2010. Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci 4:97-121.

Kilkenny, C., W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman. 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412.

Kola, I., and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715.

Kramer, M. A. 1992. Autoassociative neural networks. Comp Chem Eng 16(4):313-328.

Kumari, V., W. Soni, and T. Sharma. 1999. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156(7):1046-1051.

Landis, S. C., S. G. Amara, K. Asadullah, C. P. Austin, R. Blumenstein, E. W. Bradley, R. G. Crystal, R. B. Darnell, R. J. Ferrante, H. Fillit, R. Finkelstein, M. Fisher, H. E. Gendelman, R. M. Golub, J. L. Goudreau, R. A. Gross, A. K. Gubitz, S. E. Hesterlee, D. W. Howells, J. Huguenard, K. Kelner, W. Koroshetz, D. Krainc, S. E. Lazic, M. S. Levine, M. R. Macleod, J. M. McCall, R. T. Moxley 3rd, K. Narasimhan, L. J. Noble, S. Perrin, J. D. Porter, O. Steward, E. Unger, U. Utz, and S. D. Silberberg. 2012. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7419):187-191.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement